Literature DB >> 17556903

Metabolic and inflammatory faecal markers in collagenous colitis.

Signe Wildt1, Inge Nordgaard-Lassen, Flemming Bendtsen, Jüri J Rumessen.   

Abstract

OBJECTIVES: To evaluate the excretion of the inflammatory and metabolic faecal markers calprotectin, lactoferrin, and short-chain fatty acids in symptomatic and quiescent collagenous colitis.
METHODS: Faecal samples from 21 patients with active collagenous colitis, 12 patients retested in remission, and 13 controls were analysed. Calprotectin was determined using an enzyme-linked immunosorbent assay. Lactoferrin was estimated by a latex agglutination test. Short-chain fatty acids were determined by steam distillation followed by gas-liquid chromatography.
RESULTS: Calprotectin was increased in patients with active collagenous colitis [80 microg/g (6.25-1899)] (median and range) compared with patients with quiescent collagenous colitis [26 microg/g (6.25-340)], P=0.025 and controls [6.25 microg/g (6.25-99)], P=0.002. Eight patients (38%) with active collagenous colitis had normal levels of calprotectin. Lactoferrin was detected in one patient only. Concentrations of total short-chain fatty acids did not differ in patients with active collagenous colitis compared with quiescent collagenous colitis or controls (P=0.75), whereas concentrations of the branched-chain fatty acids were decreased in patients with active collagenous colitis versus controls (P<0.005). In-vitro incubations demonstrated increased ratios of acetate in patients with active and quiescent collagenous colitis compared with controls (P<0.05), with a corresponding decrease in branched-chain fatty acids ratios (P<0.05).
CONCLUSION: Faecal calprotectin was increased in collagenous colitis; however, increased excretion was not a universal finding limiting the use of calprotectin as an inflammatory marker in collagenous colitis. Faecal lactoferrin was almost undetectable. Luminal fermentative conditions are altered in collagenous colitis. Fermentative alterations could be secondary to changes in substrate availability and intestinal transit time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556903     DOI: 10.1097/MEG.0b013e328058ed76

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  23 in total

1.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 2.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

Review 3.  Microscopic colitis: diagnosis and management.

Authors:  Tristan Townsend; Fiona Campbell; Paul O'Toole; Chris Probert
Journal:  Frontline Gastroenterol       Date:  2018-11-27

4.  Microscopic Colitis: A Review of Collagenous and Lymphocytic Colitis.

Authors:  Karen Boland; Geoffrey C Nguyen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

5.  Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice.

Authors:  Ashwini Banerjee; M Srinivas; Richard Eyre; Robert Ellis; Norman Waugh; K D Bardhan; P Basumani
Journal:  Frontline Gastroenterol       Date:  2014-04-02

Review 6.  Diagnosis and Management of Microscopic Colitis in Pediatric Patients.

Authors:  Salina Khushal; Maria Oliva-Hemker
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

Review 7.  Diagnosis and management of microscopic colitis.

Authors:  Curt Tysk; Johan Bohr; Nils Nyhlin; Anna Wickbom; Sune Eriksson
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

8.  The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding.

Authors:  Stephan R Vavricka; Henriette Heinrich; Simon Buetikofer; Flavia Breitenmoser; Emanuel Burri; Xiaoye Schneider-Yin; Jasmin Barman-Aksoezen; Luc Biedermann; Michael Scharl; Jonas Zeitz; Gerhard Rogler; Benjamin Misselwitz; Matthias Sauter
Journal:  United European Gastroenterol J       Date:  2018-05-28       Impact factor: 4.623

9.  Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases.

Authors:  Yee Man Kan; Sin Yan Chu; Ching Kong Loo
Journal:  JGH Open       Date:  2021-05-06

10.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.